

Drug and Therapeutics Committee – Minutes –approved	
--	--

Date / Time	Thursday 11 th August 2016
Venue	The Board Room, Alderson House, HRI
Chair	Prof A Morice, Chair, Professor of Respiratory Medicine
Notes / Action Points	Mrs Vanessa Wear, PA to David Corral, Chief Pharmacist and the Pharmacy Senior Team
Quorate: Yes / No	Yes

Attendance	Mr S Gaines, Professional Secretary, Senior Principal Pharmacist – Clinical Services Mr P O'Brien, Deputy Chief Pharmacist Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics Mr R Kapur, Vascular Surgeon Mr D Roper, Chair, Hull CCG Mr K McCorry, Medicines Management, East Riding CSU Dr H Klonin, Consultant Paediatrician – Attended the meeting until 8.55am
-------------------	---

Apologies	Mrs Wendy Hornsby, Senior Pharmacy Technician Dr O Ogunbambi, Consultant Rheumatologist Prof M Lind, Vice Chair, Professor of Oncology
------------------	--


Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2016.08.01	Apologies	As above.					
2016.08.02	Declarations of Interest	AM – Lunch provided by a drug company promoting Orkambi CF medication	Noted	No further action			8/16
2016.08.03	Minutes of the previous meeting	The minutes were accepted as a true record.					8/16
2016.08.04	Action Tracker	<p>Action Tracker DC has discussed with Sarah Bates and 2 people have been suggested. DC will follow up to arrange a meeting with the suggested lay member.</p> <p>New Product Requests - Tedizolid KMcC and POB to discuss commissioning further outside meeting</p> <p>Correspondence Received SG had written to Dr Mohammed regarding the dispersible alendronic acid preparation.</p> <p>New Product Requests – 07/16 AM had written to applicants & WH had updated formulary</p> <p>Evolocumab & Alirocumab – Dr D Narayanan The two PCSK9 inhibitors had been discussed since the last committee meeting. POB informed the Committee that a pro-forma will be completed; to assess each patient is suitable before prescribing the above drugs. The patients referred to the specialist lipid clinic are expected to all be intolerant of or have failed to respond to statins, therefore fit the NICE criteria. The Committee members discussed the form. Suggestions were made to amend the form to include “patients’ past drug history”,</p>	<p>Ongoing</p> <p>Ongoing</p> <p>Action complete</p> <p>Actions complete</p> <p>Action complete</p> <p>POB to feed back pro-forma amendment to Yvonne Holloway and Dr Deepa</p>	<p></p> <p></p> <p></p> <p></p> <p>POB to feed back suggested amendment to pro-forma</p>	<p>DC</p> <p>KMcC/ POB</p> <p></p> <p>POB</p>	<p>7/16</p> <p>9/16</p> <p></p> <p>9/16</p>	<p></p> <p></p> <p>8/16</p> <p>8/16</p> <p>8/16</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p>where previous lipid-lowering agents could be recorded. A section for past medical history already exists on the form.</p> <p>Dulaglutide – Dr K Mohammed AM had written to Dr Mohammed about updating the type 2 diabetes guideline and is awaiting a response.</p> <p>NICE Guidance – 07/16</p> <ul style="list-style-type: none"> TA392 Adalimumab for treating moderate to severe hidradenitis suppurativa <p>Following the last meeting, POB had confirmed that NHSE have now identified HEY as a centre for this condition and will be commissioned to use Adalimumab in HS. POB had contacted Greg Haire to discuss the situation and a new product request had been requested from the service. It is still unclear whether this would be provided via HEY department or via Spire hospital, where much of the local dermatology service is commissioned from.</p> <p>WH had amended the formulary</p> <ul style="list-style-type: none"> TA395 Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer TA397 Belimumab for treating active autoantibody-positive systemic lupus erythematosus <p>MHRA DSU - June 16</p> <p>Cangagliflozin – risk of lower extremity amputation in high CV risk patients - AM had written to endocrinology to highlight alert.</p> <p>Nexplanon - WH had updated formulary with correct brand.</p> <p>Correspondence received – 07/16</p> <ul style="list-style-type: none"> Artesunate – POB had ordered a supply. New product request on this agenda. 	<p>Narayanan</p> <p>Action complete</p> <p>Ongoing</p> <p>Action complete</p> <p>Ongoing</p> <p>Ongoing</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p>	<p></p> <p>POB to clarify arrangements with Greg Haire</p> <p>ML to seek request</p> <p>OO to seek request</p>	<p>POB</p> <p>ML</p> <p>OO</p>	<p>8/16</p> <p>8/16</p> <p>8/16</p> <p>8/16</p> <p>8/16</p> <p>8/16</p>	<p>8/16</p> <p>8/16</p> <p>8/16</p> <p>8/16</p> <p>8/16</p> <p>8/16</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<ul style="list-style-type: none"> Everolimus – ML had provided POB with a summary of patient to send to NHSE Symbicort MDI device – WH had added to the formulary as a line extension. 	Action complete				8/16
		<ul style="list-style-type: none"> Symbicort MDI device – WH had added to the formulary as a line extension. 	Action complete				8/16
2016.08.05	New Product Requests	<ul style="list-style-type: none"> Lumicaftor-Ivacaftor (Orkambi®) – Dr D Shiferaw NICE TA398 has not recommended use of this drug for CF. However, the manufacturer is making it available on a compassionate use basis and has guaranteed the product free for life to those patients who are terminally ill or on the transplant waiting list. Despite one of the major side effects being breathlessness, AM would like to offer the drug to selected patients. It was agreed that the drug be approved subject to discussion and approval at the Hull-York Cystic Fibrosis MDT. DC reported that he is due to discuss the role of the D&T Committee at a meeting about closer working, with the Chief Pharmacist at York. Artesunate – L Cullen This product was unlicensed in the UK, but had a license in malaria prone countries. Approved for severe or complicated malaria by Infectious Diseases Department. <p>NHSE Approved HIV preparations</p> <ul style="list-style-type: none"> Daranavir/Cobicistat (Rezolsta®) – L Cullen Atazanavir/Cobicistat (Evotaz®) – L Cullen Elviregravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya®) – L Cullen <p>NHSE Approved Hepatitis C preparations</p> <ul style="list-style-type: none"> Daclatasvir (Daclinzia) – L Cullen Approved in line with NICE TA364 	Approved subject to MDT discussion & approval	WH to update formulary and Unlicensed Medicines list for all products	WH	9/16	
			Approved	AM to write to applicant	AM	9/16	
			All 3 products approved, NHSE funded in line with 16043/P and F03/P/b	AM to write to applicant	AM	9/16	
			All 4 products approved, NHSE funded in line with	AM to write to applicant	AM	9/16	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<ul style="list-style-type: none"> Ombitasvir/Paritaprevir/Ritonavir (Viekirax®) – L Cullen Approved in line with NICE TA365 Sofosbivir/Ledipasvir (Harvoni®) Approved in line with NICE TA363 Dasabuvir (Exviera®) Approved in line with NICE TA365 	B07/P/a				
2016.08.06	NICE Guidance	<p>NICE Guidance</p> <ul style="list-style-type: none"> TA387 - Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated TA398 - Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation TA399 - Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts TA400 - Nivolumab in combination with ipilimumab for treating advanced melanoma NG48 Oral Health for Adults in Care Homes NG49 Non Alcoholic Fatty Liver Disease :Assessment and Management NG50 Cirrhosis in Over 16's 	<p>NICE recommended, already on formulary</p> <p>Not recommended by NICE, but see above</p> <p>Not recommended by NICE, but formulary for TA218</p> <p>NICE recommended as option</p> <p>Primary Care only</p> <p>Drugs already on formulary</p> <p>Drugs already on</p>	<p>No further action</p> <p>No further action</p> <p>No further action</p> <p>Non formulary – Submission already requested</p> <p>No further action</p> <p>No further action</p> <p>No further</p>			<p>8/16</p> <p>8/16</p> <p>8/16</p> <p>8/16</p> <p>8/16</p> <p>8/16</p> <p>8/16</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<ul style="list-style-type: none"> • NG51 Sepsis: recognition diagnosis and early management • NG52 Non Hodgkins Lymphoma: Diagnosis and Management <p>Updates:</p> <ul style="list-style-type: none"> • NG28 Type 2 Diabetes in Adults: Management (Update) • NG17 Type 1 Diabetes in Adults: Diagnosis and Management (Update) • CG181 Cardiovascular Disease Risk Assessment and Reduction Including Lipid Modification (Update) • TA259 - Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (re-issued) • CG71 - Familial hypercholesterolaemia: identification and management (Update) • CG64 Prophylaxis against infective Endocarditis (Update) 	<p>formulary</p> <p>HEY have antibiotic guidelines, or if unknown source use IV piperacillin & tazobactam 4.5g</p> <p>Drugs already on formulary</p> <p>Minor update, does not affect formulary</p> <p>As above</p> <p>As above</p> <p>Already on formulary</p> <p>Minor update, does not affect formulary</p> <p>As above</p>	<p>action</p> <p>No further action</p> <p>No further action</p> <p>No further action</p> <p>No further action</p> <p>No further action</p> <p>No further action</p> <p>No further action</p>			<p>8/16</p> <p>8/16</p> <p>8/16</p> <p>8/16</p> <p>8/16</p> <p>8/16</p> <p>8/16</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2016.08.07	MHRA Drug Safety Update – July 16	 MHRA DSU_July_2016.pdf Warfarin & calciphylaxis, especially in end stage renal disease. NAC & biochemistry results – SG had liaised with Dr Narayanan – HEY use Beckman platforms, so do not use this system.	Highlight to Renal team	AM to write to Renal team to highlight issue	AM	8/16	
2016.08.08	Minutes from the HERPC July 2016	Under the section Feedback from Commissioning Groups (Hull and ER CCG) the following was noted: AREDs – Commissioned by Hull, not ER AREDs 2 – Not commissioned by Hull or ER DR to discuss and clarify with the CCG Prescribing Leads. DR reported that a meeting with HEY Ophthalmology department was planned to discuss treatment pathways. Regional D&TC – the situation was developing, with a consultation period planned soon.	DR to raise with CCG Prescribing Leads Await consultation	DR to raise with CCG Prescribing Leads	DR	8/16	
2016.08.09	Correspondence Received	None received					8/16
2016.08.10	Chairs approvals	<ul style="list-style-type: none"> Sulthiame – Epilepsy - Dr Jose 	Noted	No further action			8/16
2016.08.11	Issues to escalate to Operational Quality Committee	None.					8/16
2016.08.12	Any other Business	None.					8/16
2016.08.13	Date and Time of Next Meeting	Thursday 8 th September 2016, 8.15am – 9.30am. The Board Room, Alderson House, HRI					